Nyxoah Achieves Astonishing 74% Revenue Surge in Q2, Igniting Optimism for Sleep Apnea Innovation

Nyxoah (NASDAQ: NYXH), a pioneering medical technology company dedicated to addressing Obstructive Sleep Apnea (OSA), has unveiled a sensational performance for the second quarter of 2025, sending waves of excitement through the market. The company reported a remarkable 74% surge in revenue, reaching €1.5 million, a clear testament to the escalating demand for its flagship Genio® neurostimulation system.

This impressive quarterly achievement propelled Nyxoah's first-half 2025 revenue to €2.8 million, marking a robust 60% increase compared to the previous year.

The significant growth underscores the successful market penetration and clinical validation of Genio®, a minimally invasive, battery-free solution designed to provide a discreet and effective treatment for moderate to severe OSA, especially for patients who cannot tolerate Continuous Positive Airway Pressure (CPAP) therapy.

While the company's gross profit also saw a healthy rise to €1.2 million for Q2 (€2.2 million for H1), Nyxoah continues to strategically invest in its future.

The operating loss for Q2 stood at €12.2 million (with a first-half operating loss of €24.0 million), and the net loss for the quarter was €12.5 million (€24.7 million for H1). These figures reflect the company's ongoing commitment to research, development, and expanding its global footprint, necessary steps for a rapidly growing med-tech firm.

A critical highlight of Nyxoah's recent progress includes the advancement of its crucial DREAM study, which delivered compelling positive results.

This pivotal data package, showcasing the safety and efficacy of Genio®, has been successfully submitted to the U.S. Food and Drug Administration (FDA) for approval. A positive outcome from the FDA would unlock the vast and lucrative U.S. market, significantly accelerating Nyxoah's global expansion and providing a much-needed alternative for millions of American OSA sufferers.

Beyond clinical triumphs, Nyxoah is actively broadening its market access and commercialization efforts.

Reimbursement for Genio® has been secured in Belgium, opening up a new pathway for patients in the region. Furthermore, initial commercial launches have commenced in Finland, with continued strong performance observed in established markets such as Germany, Australia, Switzerland, the United Kingdom, and Canada.

These strategic expansions are crucial for Nyxoah to solidify its position as a leading innovator in the sleep apnea treatment landscape.

As of June 30, 2025, Nyxoah maintained a robust financial position with €88.3 million in cash and cash equivalents, providing a solid foundation for continued innovation and market development.

Looking ahead, the company has confidently reiterated its full-year 2025 revenue guidance, projecting figures between €7.5 million and €8.5 million. This optimistic outlook, coupled with the promising advancements in clinical trials and market access, paints a bright future for Nyxoah as it continues its mission to transform the lives of individuals living with Obstructive Sleep Apnea.